CD8A and psychotic disorder: Clinically, it has been shown to elevate peripheral CD4+ and CD8+ T cell levels while reducing Th2 cells in first‐episode psychosis patients after 4 weeks of treatment73 and to reduce circulating pro‐inflammatory factors like eotaxin and MCP‐1 in ASD patients.43